Kenvue Inc. (NYSE:KVUE) Shares Acquired by Mizuho Markets Americas LLC

Mizuho Markets Americas LLC raised its stake in shares of Kenvue Inc. (NYSE:KVUE) by 464.4% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,810,403 shares of the company’s stock after purchasing an additional 1,489,647 shares during the quarter. Kenvue comprises 0.9% of Mizuho Markets Americas LLC’s holdings, making the stock its 27th biggest position. Mizuho Markets Americas LLC owned approximately 0.09% of Kenvue worth $41,875,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also bought and sold shares of the stock. Kentucky Retirement Systems Insurance Trust Fund increased its stake in shares of Kenvue by 2.0% in the third quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 56,703 shares of the company’s stock worth $1,312,000 after acquiring an additional 1,114 shares during the period. Kentucky Retirement Systems boosted its holdings in Kenvue by 2.7% during the third quarter. Kentucky Retirement Systems now owns 133,421 shares of the company’s stock worth $3,086,000 after buying an additional 3,548 shares in the last quarter. Empowered Funds LLC boosted its holdings in Kenvue by 16.0% during the third quarter. Empowered Funds LLC now owns 149,371 shares of the company’s stock worth $3,455,000 after buying an additional 20,593 shares in the last quarter. Empirical Finance LLC lifted its holdings in Kenvue by 12.0% during the third quarter. Empirical Finance LLC now owns 25,341 shares of the company’s stock valued at $586,000 after purchasing an additional 2,721 shares in the last quarter. Finally, CIBC Asset Management Inc lifted its holdings in Kenvue by 4.5% during the third quarter. CIBC Asset Management Inc now owns 435,776 shares of the company’s stock valued at $10,079,000 after purchasing an additional 18,778 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Kenvue Price Performance

Kenvue stock opened at $23.84 on Friday. Kenvue Inc. has a 12-month low of $17.67 and a 12-month high of $24.13. The stock has a market cap of $45.70 billion, a P/E ratio of 43.34, a PEG ratio of 2.10 and a beta of 1.36. The company has a 50-day moving average price of $22.75 and a 200 day moving average price of $20.65. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66.

Kenvue (NYSE:KVUE) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business had revenue of $3.90 billion during the quarter, compared to analysts’ expectations of $3.92 billion. During the same period last year, the business earned $0.31 earnings per share. The business’s revenue for the quarter was down .4% on a year-over-year basis. Sell-side analysts anticipate that Kenvue Inc. will post 1.07 earnings per share for the current year.

Kenvue Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be paid a $0.205 dividend. This represents a $0.82 annualized dividend and a dividend yield of 3.44%. The ex-dividend date of this dividend is Wednesday, November 13th. Kenvue’s payout ratio is 149.09%.

Analyst Ratings Changes

Several research firms have issued reports on KVUE. Piper Sandler increased their price objective on shares of Kenvue from $20.00 to $21.00 and gave the company a “neutral” rating in a report on Monday, September 23rd. UBS Group increased their price objective on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Jefferies Financial Group initiated coverage on shares of Kenvue in a report on Tuesday, September 24th. They set a “buy” rating and a $27.00 price objective on the stock. JPMorgan Chase & Co. raised their price target on shares of Kenvue from $24.00 to $25.00 and gave the stock an “overweight” rating in a research note on Friday, October 11th. Finally, Deutsche Bank Aktiengesellschaft raised their price target on shares of Kenvue from $23.00 to $24.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $22.64.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.